Please login to the form below

Not currently logged in
Email:
Password:

Synthetic Biologics hires Michael Kaleko as scientific director

Co-founder of Advanced Vision Therapies joins US biotech developing synthetic DNA-based treatments

Synthetic Biologics, a US biotech specialised in developing synthetic DNA-based treatments, has appointed Dr Michael Kaleko as its new scientific director.

Kaleko, who has been a biotech consultant since 2010, has worked in gene therapy for over 20 years and previously co-founded eyecare specialist Advanced Vision Therapies in 2002, before serving as the company's president and chief scientific officer.

Prior to this he co-directed research at Genetic Therapy, a subsidiary of Novartis, where he developed multiple gene transfer and gene expression platform technologies for haemophilia, cancer, diabetes and ocular diseases.

"We are pleased to welcome Mike to the Synthetic Biologics' team,” said Jeffrey Riley, CEO and chair at Synthetic Biologics.

“We expect that Mike's significant accomplishments in the field of gene therapy will be valuable assets as we continue the work to build our portfolio of synthetic biologics and DNA-based human therapeutics."

20th April 2012

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

Here at Cuttsy+Cuttsy, we believe in making the world a better place by bringing trusted, accessible information to all and...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...